Literature DB >> 2541204

Adenovirus persistence in man. Defective E1A gene product targeting of infected cells for elimination by natural killer cells.

J M Routes1, J L Cook.   

Abstract

Human adenovirus types 2 and 5 (Ad2/5) cause persistent infections in man. Ad2/5 infection of rodent cells induces increased susceptibility to NK lymphocyte-mediated lysis that is dependent on target cell expression of Ad2/5 E1A gene products. In contrast to infected rodent cells, Ad2/5 infection of human fibroblasts and epithelial cells does not result in increased susceptibility to either human or rodent NK cell-mediated killing, despite high levels of E1A protein expression. This functional inactivity of E1A gene products in Ad-infected human cells may contribute to adenoviral persistence by rendering the NK cell response to Ad-infected cells ineffective.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541204

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Induction of sensitivity to the cytotoxic action of tumor necrosis factor alpha by adenovirus E1A is independent of transformation and transcriptional activation.

Authors:  R S Ames; B Holskin; M Mitcho; D Shalloway; M J Chen
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  Endogenous expression of E1A in human cells enhances the effect of adenovirus E3 on class I major histocompatibility complex antigen expression.

Authors:  J M Routes; B A Metz; J L Cook
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  The role of mouse adenovirus type 1 early region 1A in acute and persistent infections in mice.

Authors:  K Smith; C C Brown; K R Spindler
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

4.  Oncogenicity of human papillomavirus- or adenovirus-transformed cells correlates with resistance to lysis by natural killer cells.

Authors:  J M Routes; S Ryan
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.